Anzeige
Mehr »
Samstag, 17.01.2026 - Börsentäglich über 12.000 News
Saga Metals bestätigt weitere massive Titan-Treffer - Ressourcenmomentum nimmt Fahrt auf
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
40 Leser
Artikel bewerten:
(0)

Two Day Seminar: Lifecycle Management of Analytical Methods and Procedures According to New FDA and USP Guidelines - Opfikon, Switzerland - April 4-5, 2017 - Research and Markets

DUBLIN, Mar 06, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Lifecycle Management of Analytical Methods and Procedures - Integrate design, development, validation, and ongoing performance verification according to new FDA and USP guidelines" conference to their offering.

The 2-day workshop will give attendees the background to understand the new Analytical Procedure Lifecycle requirements and even more importantly it will focus on strategies and provide tools to implement most critical requirements. It also provides templates and examples to develop inspection ready documentation. Interactive workshop exercises will be dispersed into and between the presentations. About 50% of the total time will be dedicated to practical sessions with life examples.. After the course a variety of tools such as SOPs, validation examples and checklists will be readily available at no additional cost on a dedicated website that can be used by attendees to easily implement what they have learned in the course.

Results of analytical methods and procedures are used as the key basis to make important decision during development and manufacturing of pharmaceutical products. Therefore all regulatory agencies expect the regulated industry to have procedures and measurements in place to ensure highest reliability, accuracy and precision of such methods and procedures. The procedures should cover all lifecycle phases from design, development, validation to on-going routine use.

Managing analytical methods and procedures according to the lifecycle approach got highest attention from regulatory agencies and industry task forces. For example, the new FDA guidance Analytical Procedures and Methods Validation for Drugs and Biologics starts with suggestions for method development and includes a chapter on Lifecycle Management of Analytical Procedures. USP's Validation and Verification Expert panel just proposed a new general chapter 1220: The Analytical Procedure Lifecycle.

Attendees will:

- Learn about the regulatory background and requirements for managing the lifecycle of analytical methods and procedures
- Understand current and future industry trends: revised USP chapters 1225 and proposed chapter 1220: "The Analytical Procedure Lifecycle", and Quality by Design (QbD) principles for method development and validation
- Learn how to plan, execute and document design, development and validation of methods developed in-house
- Understand the principles of lifecycle management for compendial procedures and for managing method transfer
- Be able to explain your company's strategy for analytical procedure lifecycle
- Understand risk management strategies throughout the procedure lifecycle
- Be able to design and execute a procedure specific control strategy based on risk
- Be able to justify and document decisions about type and extend of revalidation after method changes
- Be able to define and demonstrate FDA, EU, USP and ICH compliance to auditors and inspectors
- Be able to develop inspection ready documentation during on-going routine operation
- Understanding what questions will be asked during audits and inspections and how to answer them

Who Should Attend:

- QA managers and personnel
- Quality control
- Method development
- Analytical chemists
- Validation specialists
- Laboratory managers and supervisors
- Regulatory affairs
- Training departments
- Documentation departments
- Consultants

Agenda:

The concept: 50 % of the time will be dedicated workshop type exercises using prepared fill-in templates and to interactive discussions.

Day 01 (8:30 AM - 4:30 PM)

08.30 AM - 09.00 AM: Registration

Introductions and Agenda Review

Lectures and Workshop Exercises

Lecture 1: Regulatory background and requirements

Lecture 2: Going through the new FDA Method Validation guidance - with focus on procedure lifecycle recommendations

Lecture 3: Preparing your lab for compliant validation studies

Lecture 4: The lifecycle overview on integrated design development, validation, and on ongoing performance verification

Day 02 (8:30 AM - 4:30 PM)

Lectures and Workshop Exercises

Lecture 5: The analytical target profile

Lecture 6: Procedure design and development

Lecture 7: Procedure Performance Qualification (Validation)

Lecture 8: Ongoing Performance Verification

For more information about this conference visit http://www.researchandmarkets.com/research/dmc5l6/lifecycle

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

© 2017 PR Newswire
Renditeturbo 2026 - 5 Aktien mit Potenzial
2025 neigt sich dem Ende zu, ohne klassische Jahresendrallye, aber mit einem DAX, der viele Kritiker Lügen gestraft hat. Über 21 Prozent Kursplus seit Jahresbeginn, stärker als der US-Markt. Wer hätte das noch vor Monaten erwartet?

Genau solche Entwicklungen machen den Reiz der Börse aus. Denn auch 2026 dürfte wieder alles anders kommen als gedacht. Während viele Analysten weiter steigende Kurse erwarten, rückt eine zentrale Frage in den Fokus: Wo entstehen im kommenden Jahr echte Überraschungen, und wie kann man davon profitieren?

Unser aktueller Spezialreport beleuchtet fünf Entwicklungen, mit denen kaum jemand rechnet, die aber enormes Renditepotenzial bergen. Vom Comeback der Ölwerte über unterschätzte Plattform-Aktien bis hin zur möglichen Wachablösung im KI-Sektor: Wer 2026 überdurchschnittlich abschneiden will, muss antizyklisch denken und frühzeitig Position beziehen.

Im kostenlosen Report stellen wir 5 Aktien vor, die 2026 im Zentrum solcher Wendepunkte stehen könnten. Solide bewertet, gut positioniert und mit überraschend starkem Momentum.

Jetzt kostenlos herunterladen! Bevor andere erkennen, wo die Chancen wirklich liegen!

Dieses exklusive PDF ist nur für kurze Zeit verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.